[1]冯会 孙建平 段薇.甲状腺相关眼病治疗新进展[J].国际内分泌代谢杂志,2020,40(02):104-107.[doi:10.3760/cma.j.issn.1673-4157.2020.02.008]
　Feng Hui,Sun Jianping,Duan Wei.New progress in the treatment of thyroid-associated ophthalmopathy[J].International Journal of Endocrinology and Metabolism,2020,40(02):104-107.[doi:10.3760/cma.j.issn.1673-4157.2020.02.008]
点击复制

甲状腺相关眼病治疗新进展()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
40
期数:
2020年02期
页码:
104-107
栏目:
综述
出版日期:
2020-03-20

文章信息/Info

Title:
New progress in the treatment of thyroid-associated ophthalmopathy
作者:
冯会 孙建平 段薇
大连大学附属中山医院内分泌科 116001
Author(s):
Feng Hui;  Sun Jianping;  Duan Wei
Department of Endocrinology, The Affiliated Zhongshan Hospital of Dalian University, Dalian 116001, China
关键词:
甲状腺相关眼病;  Graves眼病;  自身免疫
Keywords:
Thyroid-associated ophthalmopathy;  Graves' orbitopathy;  Autoimmunity
DOI:
10.3760/cma.j.issn.1673-4157.2020.02.008
摘要:
甲状腺相关眼病(TAO)是临床常见、发病率高的自身免疫性眼眶疾病,糖皮质激素是一线主流用药,鉴于使用者对其不良反应的忌惮以及部分患者对糖皮质激素治疗的不敏感,目前,已有诸多可改善TAO进程的药物在研发和临床应用前期中:从拮抗白细胞介素(IL)-6受体和肿瘤坏死因子(TNF)-α等免疫靶向治疗,到阻滞促甲状腺激素(TSH)受体产生甲状腺自身抗体; 从拮抗胰岛素样生长因子(IGF)-1受体减少眼眶成纤维细胞活化,到锝-亚甲基二磷酸盐注射液(99Tc-MDP)、他汀类等调节自身免疫炎性反应,甚至从有效治疗Graves病的免疫疗法中也可以寻找到有望解决TAO的方法。
Abstract:
Thyroid-associated ophthalmopathy(TAO)is an autoimmune disorder of the orbit with high incidence. Glucocorticoids are the first choice of mainstream medicine for TAO. But because of side effects and the insensitivity of glucocorticoids in patients with TAO, many new drugs improving TAO have been researched and applied in pre-clinical trial in recent years:from interleukin-6 receptor and tumor necrosis factor-α in immunotargeted therapies to blocker of thyroid stimulating hormone receptor(TSHR)production, from antagonizer of insulin-like growth factor 1 receptor reducing the activation of orbital fibroblasts to 99Tc-MDP(99Technetium-Methylenediphosphonate), statins which regulate autoimmune response. And even more, those effective immunoregulating medicine for Graves' disease are expected promising solutions to TAO.

参考文献/References:

[1] Kumar S,Bahn RS.Relative overexpression of macrophage-derived cytokines in orbital adipose tissue from patients with Graves' ophthalmopathy[J].J Clin Endocrinol Metab,2003,88(9):4246-4250.DOI:10.1210/jc.2003-030380.
[2] Kaneko A. Tocilizumab in rheumatoid arthritis: efficacy, safety and its place in therapy[J].Ther Adv Chronic Dis,2013,4(1):15-21.DOI:10.1177/2040622312466908.
[3] Pérez-Moreiras JV,Alvarez-López A,Gómez EC.Treatment of active corticosteroid-resistant Graves' orbitopathy[J].Ophthalmic Plast Reconstr Surg,2014,30(2):162-167. DOI:10.1097/IOP.0000000000000037.
[4] Sy A,Eliasieh K,Silkiss RZ.Clinical response to tocilizumab in severe thyroid eye disease[J].Ophthalmic Plast Reconstr Surg,2017,33(3):e55-e57.DOI:10.1097/IOP.0000000000000730.
[5] Laura Chadwick, Sizheng Zhao, Eduardo Mysler,et al.Review of biosimilar trials and data on etanercept in rheumatoid arthritis[J].Curr Rheumatol Rep,2018,20(12):84.DOI:10.1007/s11926-018-0799-0.
[6] Paridaens D,van den Bosch WA,van der Loos TL,et al.The effect of etanercept on Graves' ophthalmopathy: a pilot study[J].Eye(Lond),2005,19(12):1286-1289.DOI:10.1038/sj.eye.6701768.
[7] Durrani OM,Reuser TQ,Murray PI.Infliximab:a novel treatment for sight-threatening thyroid associated ophthalmopathy[J].Orbit,2005,24(2):117-119.DOI:10.1080/01676830590912562.
[8] Douglas RS,Naik V,Hwang CJ,et al.B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis[J].J Immunol,2008,181(8):5768-5774.DOI:10.4049/jimmunol.181.8.5768.
[9] Smith TJ,Kahaly GJ,Ezra DG,et al.Teprotumumab for thyroid-associated ophthalmopathy[J].N Engl J Med,2017,376(18):1748-1761.DOI:10.1056/NEJMoa1614949.
[10] Douglas RS.Teprotumumab,an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease:a focus on proptosis[J].Eye(Lond),2019,33(2):183-190.DOI:10.1038/s41433-018-0321-y.
[11] Rootman DB,Golan S,Pavlovich P,et al.Postoperative changes in strabismus, ductions, exophthalmometry, and eyelid retraction after orbital decompression for thyroid orbitopathy[J].Ophthalmic Plast Reconstr Surg,2017,33(4):289-293.DOI:10.1097/IOP.0000000000000758.
[12] Wu CY, Niziol LM, Musch DC, et al. Thyroid-related orbital decompression surgery:a multivariate analysis of risk factors and outcomes[J].Ophthal Plast Reconstr Surg,2017,33(3):189-195.DOI:10.1097/IOP.0000000000000699.
[13] Ulrich P,Flandre T,Espie P,et al.Nonclinical safety assessment of CFZ533, a Fc-Silent Anti-CD40 antibody, in cynomolgus monkeys[J].Toxicol Sci,2018,166(1):192-202.DOI:10.1093/toxsci/kfy196.
[14] Beecher G,Putko BN,Wagner AN,et al.Therapies directed against B-cells and downstream effectors in generalized autoimmune myasthenia gravis: current status[J].Drugs,2019,79(4):353-364.DOI:10.1007/s40265-019-1065-0.
[15] Pearce SHS,Dayan C,Wraith DC,et al.Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves' hyperthyroidism: aphase Ⅰ study[J].Thyroid,2019,29(7):1003-1011.DOI:10.1089/thy.2019.0036.
[16] Sanders P,Young S,Sanders J,et al.Crystal structure of the TSH receptor(TSHR)bound to a blocking-type TSHR autoantibody[J].J Mol Endocrinol,2011,46(2):81-99. DOI:10.1530/JME-10-0127.
[17] Sanders P,Young S,Sanders J,et al.Crystal structure of the TSH receptor(TSHR)bound to a blocking-type TSHR autoantibody[J].J Mol Endocrinol,2011,46(2):81-99.DOI:10.1530/JME-10-0127.
[18] 吴永刚,马琦琳,刘国锋,等.“云克”对白细胞介素(IL)-1β刺激的人眼球后成纤维细胞的影响[J].中国现代医学杂志,2002,12:62-63.
[19] 欧阳伟,冯会娟,刘金华,等.云克治疗免疫抑制疗法无效Graves'眼病的临床疗效[J].南方医科大学学报,2008,28(10):1921-1922. DOI:10.3321/j.issn.1673-4254.2008.10.045.
[20] Bedi O,Dhawan V,Sharma PL,et al.Pleiotropic effects of statins:new therapeutic targets in drug design[J].Naunyn Schmiedebergs Arch Pharmacol,2016,389(7):695-712.DOI:10.1007/s00210-016-1252-4.
[21] Busnelli M,Manzini S,Froio A,et al.Diet induced mild hypercholesterolemia in pigs: local and systemic inflammation, effects on vascular injury-rescue by high-dose statin treatment[J].PLoS One,2013,8(11):e80588.DOI:10.1371/journal.pone.0080588.
[22] Bedi O,Dhawan V,Sharma PL,et al.Pleiotropic effects of statins:new therapeutic targets in drug design[J].Naunyn Schmiedebergs Arch Pharmacol,2016,389(7):695-712.DOI:10.1007/s00210-016-1252-4.
[23] Stein JD,Childers D,Gupta S,et al.Risk factors for developing thyroid-associated ophthalmopathy among individualswith Graves' disease[J].JAMA Ophthalmol,2015,133(3):290-296.DOI:10.1001/jamaophthalmol.2014.5103.
[24] Reynolds AL,Del Monte MA,Archer SM.The effect of oral statin therapy on strabismus in patients with thyroid eye disease[J].J AAPOS,2018,22(5):340-343. DOI:10.1016/j.jaapos.2018.04.009.

相似文献/References:

[1]韩煦,魏军平.促甲状腺激素受体抗体的检测及其在Graves病 诊疗中的价值[J].国际内分泌代谢杂志,2017,37(02):94.[doi:10.3760/cma.j.issn.1673-4157.2017.02.006]
　Han Xu,Wei Junping..Thyroid stimulating hormone receptor antibodies assays and its clinical significance in Graves' disease[J].International Journal of Endocrinology and Metabolism,2017,37(02):94.[doi:10.3760/cma.j.issn.1673-4157.2017.02.006]
[2]王小凤,刘晶,罗桑曲珍,等.他汀类药物用于甲状腺相关性眼病的研究进展[J].国际内分泌代谢杂志,2023,43(04):330.[doi:10.3760/cma.j.cn121383-20220406-04015]
　Wang Xiaofeng,Liu Jing,Luo Sangquzhen,et al.Research progress of statins for thyroid related eye diseases[J].International Journal of Endocrinology and Metabolism,2023,43(02):330.[doi:10.3760/cma.j.cn121383-20220406-04015]

备注/Memo

备注/Memo:
通信作者:段薇,Email:duanwei34@hotmail.com
基金项目:大连市科技创新基金项目(2019J13SN107)
Corresponding author: Duan Wei,Email:duanwei34@hotmail.com
Fund program:Dalian Science and Technology Innovation Fund Project(2019J13SN107)
更新日期/Last Update: 2020-03-20